Management of precancerous conditions and lesions in the stomach (MAPS): Guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)

Virchows Archiv

Volumn 460, Issue 1, 2012, Pages 19-46

  Dinis Ribeiro, M ^a   Areia, M ^b   De Vries, A C ^c   Marcos Pinto, R ^d,f   Monteiro Soares, M ^e   O'Connor, A ^g   Pereira, C ^a   Pimentel Nunes, P ^a   Correia, R ^e   Ensari, A ^h   Dumonceau, J M ⁱ   MacHado, J C ^f   MacEdo, G ^j   Malfertheiner, P ^k   Matysiak Budnik, T ^l   Megraud, F ^m   Miki, K ⁿ   O'Morain, C ^g   Peek, R M ^o   Ponchon, T ^p   Ristimaki, A ^q,r   Rembacken, B ^s   Carneiro, F ^j   Kuipers, E J ^c   more..

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Institute of Biomedical Sciences Abel Salazar   (Portugal)

^e University of Porto   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

^g ADELAIDE AND MEATH HOSPITAL   (Ireland)

^h ANKARA UNIVERSITY   (Turkey)

ⁱ Hôpital Cantonal   (Switzerland)

^j Universidade do Porto   (Portugal)

^k OTTO VON GUERICKE UNIVERSITY   (Germany)

^l HÔTEL DIEU   (France)

^m UNIVERSITÉ DE BORDEAUX   (France)

ⁿ Japan Research Foundation of Prediction   (Japan)

^o VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p EDOUARD HERRIOT HOSPITAL   (France)

^q HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^r UNIVERSITY OF HELSINKI   (Finland)

^s LEEDS GENERAL INFIRMARY   (United Kingdom)

more..

Author keywords

Atrophic gastritis; Diagnosis; Dysplasia; Endoscopy; Follow up; Gastric cancer; Guideline; Helicobacter pylori; Intestinal metaplasia; Management; Pepsinogen; Precancerous conditions; Precancerous lesions; Therapy

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CELECOXIB; ETODOLAC; MUCIN 1; MUCIN 2; MUCIN 5AC; MUCIN 6; PEPSINOGEN I; PEPSINOGEN II; ROFECOXIB; SELENIUM; SIALOMUCIN; SULFOMUCIN;

ARTICLE; ATROPHIC GASTRITIS; ATROPHY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CHEMOPROPHYLAXIS; CHROMOENDOSCOPY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ENDOSCOPIC SURGERY; EPITHELIUM DYSPLASIA; ERADICATION THERAPY; EVIDENCE BASED PRACTICE; FAMILY HISTORY; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HEALTH CARE COST; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MEDICAL SOCIETY; META ANALYSIS (TOPIC); NONHUMAN; PEPSIN SECRETION; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH ATROPHY; STOMACH CANCER; SYSTEMATIC REVIEW (TOPIC); WHITE LIGHT ENDOSCOPY;

ATROPHY; ENDOSCOPY, GASTROINTESTINAL; EUROPE; GASTRITIS; HUMANS; METAPLASIA; PORTUGAL; PRECANCEROUS CONDITIONS; RISK FACTORS; SOCIETIES, MEDICAL; STOMACH; STOMACH NEOPLASMS;

EID: 84857049101     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-011-1177-8     Document Type: Article

References (272)

1. Correa P (1988) A human model of gastric carcinogenesis. Cancer Res 48:3554-3560
2. Collaboration AGREE (2003) Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 12:18-23
3. Atkins D, Best D, Briss PA, Working Group GRADE et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328:1490
4. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, GRADE working group (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924-926 (Pubitemid 351632017)
5. Harbour R, Miller J (2001) A new system for grading recommendations in evidence-based guidelines. BMJ 323:334-336 (Pubitemid 32744465)
6. Correa P (1992) Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52:6735-6740 (Pubitemid 23006271)
7. Kapadia CR (2003) Gastric atrophy, metaplasia and dysplasia. A clinical perspective. J Clin Gastroenterol 36:S29-S36 (Pubitemid 36459117)
8. Carneiro F, Machado JC, David L, Reis C, Nogueira AM, Sobrinho-Simões M (2001) Current thoughts on the histopathogenesis of gastric cancer. Eur J Cancer Prev 10:101-102 (Pubitemid 32200209)
9. Ihamäki T, Saukkonen M, Siurala M (1978) Long term observation of subjects with normal mucosa and with superficial gastritis: results of 23-27 years follow-up examination. Scand J Gastroenterol 13:771-775 (Pubitemid 9067120)
10. Ormiston MC, GearMW, Codling BW(1982) Five year follow-up study of gastritis. J Clin Pathol 35:757-760 (Pubitemid 12092663)
11. Laurén P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 64:31-49
12. Fukao A, Hisamichi S, Ohsato M, Fujino N, Endo N, Iha M (1993) Correlation between the prevalence of gastritis and gastric cancer in Japan. Cancer Causes Control 4:17-20 (Pubitemid 23051893)
13. Genta RM (1998) Review article: gastric atrophy and atrophic gastritis-nebulous concepts in search of a definition. Aliment Pharmacol Ther 12:17-23
14. Dixon MF, Genta RM, Yardley JH, Correa P (1994) Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20:1161-1181
15. Misiewicz JJ (1991) The Sydney System: a new classification of gastritis. Introduction. J Gastroenterol Hepatol 6:207-208
16. Plummer M, Buiatti E, Lopez G, Peraza S, Vivas J, Oliver W, Muñoz N (1997) Histological diagnosis of precancerous lesions of the stomach: a reliability study. Int J Epidemiol 26:716-720 (Pubitemid 27367846)
17. Filipe MI, Potet F, Bogomoletz WV, Dawson PA, Fabiani B, Chauveinc P, Fenzy A, Gazzard B, Golfain D, Zeegen R (1985) Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut 26:1319-1326 (Pubitemid 16134454)
18. Filipe MI, Barbatis C, Sandey A, Ma J (1988) Expression of intestinal mucin antigens in the gastric epithelium and its relationship with malignancy. Hum Pathol 19:19-26 (Pubitemid 18065866)
19. Silva S, Filipe MI, Pinho A (1990) Variants of intestinal metaplasia in the evolution of chronic atrophic gastritis and gastric alcer. A follow up study. Gut 31:1097-1104 (Pubitemid 20343047)
20. Reis CA, David L, Correa P, Carneiro F, de Bolós C, Garcia E, Mandel U, Clausen H, Sobrinho-Simões M (1999) Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC and MUC6) expression. Cancer Res 59:1003-1007 (Pubitemid 29135958)
21. Gutiérrez-González L, Wright NA (2008) Biology of intestinal metaplasia in 2008: more than a simple phenotypic alteration. Dig Liver Dis 40:510-522
22. Correa P (1985) Clinical implications of recent developments in gastric cancer pathology and epidemiology. Semin Oncol 12:2-10 (Pubitemid 15101318)
23. Genta RM, Rugge M (1999) Gastric precancerous lesions: heading for an international consensus. Gut 45:I5-I8 (Pubitemid 29297996)
24. Guindi M, Riddell RH (2001) The pathology of epithelial premalignancy of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 15:191-210 (Pubitemid 32573852)
25. Riddell RH (1996) Premalignant and early malignant lesions in the gastrointestinal tract: definitions, terminology and problems. Am J Gastroenterol 91:864-872 (Pubitemid 26143521)
26. Odze RD, Riddell RH, Bosman FT, Carneiro F, Fléjou J-F, Geboes K, Genta RM, Hattori T, Hruban RH, van Krieken JHJM, Lauwers GY, Offerhaus GJA, Rugge M, Shimizu M, Shimoda T, Theise ND, Vieth M (2010) Premalignant lesions of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumours of the digestive system, 4th edn. IARC, Lyon
27. Park SY, Jeon SW, Jung MK, Cho CM, Tak WY, Kweon YO, Kim SK, Choi YH (2008) Long-term follow-up study of gastric intraepithelial neoplasias: progression from low-grade dysplasia to invasive carcinoma. Eur J Gastroenterol Hepatol 20:966-970
28. de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ (2008) Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 134:945-952 (Pubitemid 351451990)
29. Yamada H, Ikegami M, Shimoda T, Takagi N, Maruyama M (2004) Long-term follow-up study of gastric adenoma/dysplasia. Endoscopy 36:390-396 (Pubitemid 38578884)
30. Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, Guilherme M, Barbosa J, Lomba-Viana H, Silva R, Moreira-Dias L (2004) A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol 57:177-182 (Pubitemid 38177758)
31. Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW (2002) The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 50:378-381 (Pubitemid 34161055)
32. You WC, Li JY, Blot WJ et al (1999) Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer 83:615-619 (Pubitemid 29508039)
33. Kokkola A, Haapiainen R, Laxén F, Puolakkainen P, Kivilaakso E, Virtamo J, Sipponen P (1996) Risk of gastric carcinoma in patients with mucosal dysplasia associated with atrophic gastritis: a follow-up study. J Clin Pathol 49:979-984 (Pubitemid 27273808)
34. Rugge M, Farinati F, Baffa R, Sonego F, Di Mario F, Leandro G, Valiante F (1994) Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology 107:1288-1296 (Pubitemid 24328264)
35. Bearzi I, Brancorsini D, Santinelli A, Rezai B, Mannello B, Ranaldi R (1994) Gastric dysplasia: a ten-year follow-up study. Pathol Res Pract 190:61-68 (Pubitemid 24106587)
36. Di Gregorio C, Morandi P, Fante R, De Gaetani C (1993) Gastric dysplasia. A follow-up study. Am J Gastroenterol 88:1715-1719
37. Fertitta AM, Comin U, Terruzzi V et al (1993) Clinical significance of gastric dysplasia: a multicenter follow-up study. Gastrointestinal Endoscopic Pathology Study Group. Endoscopy 25:265-268 (Pubitemid 23184553)
38. Farinati F, Rugge M, Di Mario F, Valiante F, Baffa R (1993) Early and advanced gastric cancer in the follow-up ofmoderate and severe gastric dysplasia patients. A prospective study. I.G.G.E.D.-Interdisciplinary Group on Gastric Epithelial Dysplasia. Endoscopy 25:261-264 (Pubitemid 23184552)
39. Rugge M, Farinati F, Di Mario F, Baffa R, Valiante F, Cardin F (1991) Gastric epithelial dysplasia: a prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia. Hum Pathol 22:1002-1008
40. Rugge M, Baffa R, Farinati F, Di Mario F, Guido M, Valiante F, Ninfo V (1991) Epithelial dysplasia in atrophic gastritis. Bioptical follow-up study. Ital J Gastroenterol 23:70-73
41. Koch HK, Oehlert M, Oehlert W (1990) An evaluation of gastric dysplasia in the years 1986 and 1987. Pathol Res Pract 186:80-84 (Pubitemid 20097949)
42. Lansdown M, Quirke P, Dixon MF, Axon AT, Johnston D (1990) High grade dysplasia of the gastric mucosa: a marker for gastric adenocarcinoma. Gut 31:977-983 (Pubitemid 20295928)
43. Coma del Corral MJ, Pardo-Mindan FJ, Razquin S, Ojeda C (1990) Risk of cancer in patients with gastric dysplasia. Followup study of 67 patients. Cancer 65:2078-2085 (Pubitemid 20147652)
44. Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, Tannenbaum S, Collazos T, Ruiz B (1990) Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 50:4737-4740 (Pubitemid 20230422)
45. Saraga EP, Gardiol D, Costa J (1987) Gastric dysplasia. A histological follow-up study. Am J Surg Pathol 11:788-796 (Pubitemid 17143585)
46. Andersson AP, Lauritsen KB, West F, Johansen A (1987) Dysplasia in gastric mucosa: prognostic significance. Acta Chir Scand 153:29-31 (Pubitemid 17038261)
47. Aste H, Sciallero S, Pugliese V, Gennaro M (1986) The clinical significance of gastric epithelial dysplasia. Endoscopy 18:174-176 (Pubitemid 16014614)
48. Farini R, Pagnini CA, Farinati F, Di Mario F, Cardin F, Vianello F, Rugge M, Naccarato R (1983) Is mild gastric epithelial dysplasia an indication for follow-up? J Clin Gastroenterol 5:307-310 (Pubitemid 13073842)
49. Riddell RH, Goldman H, Ransohoff DF et al (1983) Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14:931-968
50. Lauwers GY, Shimizu M, Correa P et al (1999) Evaluation of gastric biopsies for neoplasia: differences between Japanese and Western pathologists. Am J Surg Pathol 23:511-518 (Pubitemid 29214952)
51. Lauwers GY, Carneiro F, Graham DY, Curado M-P, Franceschi S, Montgomery E, Tatematsu M, Hattori T (2010) Gastric carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO Classification of tumours of the digestive system, 4th edn. IARC, Lyon, pp 48-58
52. Atkins L, Benedict EB (1956) Correlation of gross gastroscopic findings with gastroscopic biopsy in gastritis. N Engl J Med 254:641-644
53. Bah A, Saraga E, Armstrong D, Vouillamoz D, Dorta G, Duroux P, Weber B, Froehlich F, Blum AL, Schnegg JF (1995) Endoscopic features of Helicobacter pylori-related gastritis. Endoscopy 27:593-596
54. Calabrese C, Di Febo G, Brandi G, Morselli-Labate AM, Areni A, Scialpi C, Biasco G, Miglioli M (1999) Correlation between endoscopic features of gastric antrum, histology and Helicobacter pylori infection in adults. Ital J Gastroenterol Hepatol 31:359-365 (Pubitemid 29366663)
55. Carpenter HA, Talley NJ (1995) Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology 108:917-924
56. Loffeld RJ (1999) Diagnostic value of endoscopic signs of gastritis: with special emphasis to nodular antritis. Neth J Med 54:96-100 (Pubitemid 29114981)
57. Redéen S, Petersson F, Jönsson KA, Borch K (2003) Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample. Endoscopy 35:946-950 (Pubitemid 37368820)
58. Stathopoulos G, Goldberg RD, Blackstone MO (1990) Endoscopic diagnosis of intestinal metaplasia. Gastrointest Endosc 36:544-545 (Pubitemid 20349160)
59. Eshmuratov A, Nah JC, Kim N et al (2010) The correlation of endoscopic and histological diagnosis of gastric atrophy. Dig Dis Sci 55:1364-1375
60. Yan SL, Wu ST, Chen CH, Hung YH, Yang TH, Pang VS, Yeh YH(2010)Mucosal patterns of Helicobacter pylori-related gastritis without atrophy in the gastric corpus using standard endoscopy. World J Gastroenterol 16:496-500
61. Laine L, Cohen H, Sloane R, Marin-Sorensen M, Weinstein WM (1995) Interobserver agreement and predictive value of endoscopic findings for H. pylori and gastritis in normal volunteers. Gastrointest Endosc 42:420-423
62. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C et al (2003) Magnification chromoendoscopy for the diagnosis of gastric intestinal metaplasia and dysplasia. Gastrointest Endosc 57:498-504 (Pubitemid 36402715)
63. Areia M, Amaro P, Dinis-Ribeiro M et al (2008) External validation of a classification for methylene blue magnification chromoendoscopy in premalignant gastric lesions. Gastrointest Endosc 67:1011-1018 (Pubitemid 351728107)
64. Mouzyka S, Fedoseeva A (2008) Chromoendoscopy with hematoxylin in the classification of gastric lesions. Gastric Cancer 11:15-21, discussion 21-22 (Pubitemid 351464477)
65. Tanaka K, Toyoda H, Kadowaki S, Hamada Y, Kosaka R, Matsuzaki S, Shiraishi T, Imoto I, Takei Y (2008) Surface pattern classification by enhanced magnification endoscopy for identifying early gastric cancers. Gastrointest Endosc 67:430-437 (Pubitemid 351253651)
66. Anagnostopoulos GK, Yao K, Kaye P et al (2007) Highresolution magnification endoscopy can reliably identify normal gastric mucosa, Helicobacter pylori-associated gastritis, and gastric atrophy. Endoscopy 39:202-207 (Pubitemid 46510790)
67. Gonen C, Simsek I, Sarioglu S, Akpinar H (2009) Comparison of high resolution magnifying endoscopy and standard videoendoscopy for the diagnosis of Helicobacter pylori gastritis in routine clinical practice: a prospective study. Helicobacter 14:12-21
68. Tahara T, Shibata T, Nakamura M, Yoshioka D, Okubo M, Arisawa T, Hirata I (2009) Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis. Gastrointest Endosc 70:246-253
69. Bansal A, Ulusarac O, Mathur S, Sharma P (2008) Correlation between narrow band imaging and nonneoplastic gastric pathology: a pilot feasibility trial. Gastrointest Endosc 67:210-216
70. Kato M, Kaise M, Yonezawa J, Toyoizumi H, Yoshimura M, Yoshida Y, Kawamura M, Tajiri H (2010) Magnifying endoscopy with narrow-band imaging achieves superior accuracy in the differential diagnosis of superficial gastric lesions identified with white-light endoscopy: a prospective study. Gastrointest Endosc 72:523-529
71. Ezoe Y, Muto M, Horimatsu T, Minashi K, Yano T, Sano Y, Chiba T, Ohtsu A (2010) Magnifying narrow-band imaging versus magnifying white-light imaging for the differential diagnosis of gastric small depressive lesions: a prospective study. Gastrointest Endosc 71:477-484
72. Kadowaki S, Tanaka K, Toyoda H et al (2009) Ease of early gastric cancer demarcation recognition: a comparison of four magnifying endoscopy methods. J Gastroenterol Hepatol 24:1625-1630
73. Uedo N, Ishihara R, Iishi H et al (2006) A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. Endoscopy 38:819-824 (Pubitemid 44314637)
74. Okubo M, Tahara T, Shibata T, Nakamura M, Yoshioka D, Maeda Y, Yonemura J, Ishizuka T, Arisawa T, Hirata I (2011) Changes in gastric mucosal patterns seen by magnifying NBI during H. pylori eradication. J Gastroenterol 46:175-182
75. Kaise M, Kato M, Urashima M et al (2009) Magnifying endoscopy combined with narrow-band imaging for differential diagnosis of superficial depressed gastric lesions. Endoscopy 41:310-315
76. Capelle LG, Haringsma J, da Vries AC, Steyerberg EW, Biermann K, van Dekken H, Kuipers EJ (2010) Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy. Dig Dis Sci 55:3442-3448
77. Alaboudy AA, Elbahrawy A, Matsumoto S, Yoshizawa A (2011) Conventional narrow-band imaging has good correlation with histopathological severity of Helicobacter pylori gastritis. Dig Dis Sci 56:1127-1130
78. Eriksson NK, Färkkilä MA, Voutilainen ME, Arkkila PE (2005) The clinical value of taking routine biopsies from the incisura angularis during gastroscopy. Endoscopy 37:532-536 (Pubitemid 40775236)
79. Guarner J, Herrera-Goepfert R, Mohar A, Smith C, Schofield A, Halperin D, Sanchez L, Parsonnet J (2003) Diagnostic yield of gastric biopsy specimens when screening for preneoplastic lesions. Hum Pathol 34:28-31 (Pubitemid 36160018)
80. el-Zimaity HM, Graham DY (1999) Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System. Hum Pathol 30:72-77 (Pubitemid 29037397)
81. Rugge M, Genta RM (2005) Staging and grading of chronic gastritis. Hum Pathol 36:228-233 (Pubitemid 40404005)
82. Kashin S, Pavlov A, Gono K, Nadezhin A (2010) Endoscopic diagnosis of early gastric cancer and gastric precancerous lesions. In: Pasechnikov VD (ed) Gastric cancer: diagnosis, early prevention, and treatment, 1st edn. Nova Science, Hauppauge, pp 197- 233
83. Satoh K, Kimura K, Taniguchi Yet al (1998) Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol 93:569-573 (Pubitemid 29081004)
84. de Vries AC, Haringsma J, de Vries RA, Ter Borg F, van Grieken NC, Meijer GA, van Dekken H, Kuipers EJ (2010) Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. Helicobacter 15:259-264
85. Rugge M, Cassaro M, Pennelli G, Leandro G, Di Mario F, Farinati F (2003) Atrophic gastritis: pathology and endoscopy in the reversibility assessment. Gut 52:1387-1388 (Pubitemid 37026482)
86. Ricuarte O, Gutierrez O, Cardona H, Kim JG, Dy G, el-Zimaity HM (2005) Atrophic gastritis in young children and adolescents. J Clin Pathol 58:1189-1193 (Pubitemid 41566465)
87. You WC, Blot WJ, Li JY et al (1993) Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res 53:1317-1321 (Pubitemid 23097109)
88. Dursun M, Yilmaz S, Yükselen V, Kilinç N, Canoruç F, Tuzcu A (2004) Evaluation of optimal gastric mucosal biopsy site and number for identification of Helicobacter pylori, gastric atrophy and intestinal metaplasia. Hepatogastroenterology 51:1732-1735 (Pubitemid 39389769)
89. el-Zimaity HM, al-Assi MT, Genta RM, Graham DY (1995) Confirmation of successful therapy of Helicobacter pylori infection: number and site of biopsies or a rapid urease test. Am J Gastroenterol 90:1962-1964
90. el-Zimaity HM, Ota H, Graham DY, Akamatsu T, Katsuyama T (2002) Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer 94:1428-1436 (Pubitemid 34212636)
91. el-Zimaity HM, Ramchatesingh J, Saeed MA, Graham DY (2001) Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol 54:679-683 (Pubitemid 32835414)
92. Rugge M, Correa P, Di Mario F et al (2008) OLGA staging for gastritis: a tutorial. Dig Liver Dis 40:650-658
93. Rugge M, Genta RM, OLGA group (2005) Staging gastritis: an international proposal. Gastroenterology 129:1807-1808
94. Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G, Graham DY (2007) Gastritis staging in clinical practice: the OLGA staging system. Gut 56:631-636 (Pubitemid 46662927)
95. Satoh K, Osawa H, Yoshizawa M, Nakano H, Hirasawa T, Kihira K, Sugano K (2008) Assessment of atrophic gastritis using the OLGA system. Helicobacter 13:225-229 (Pubitemid 351667074)
96. Rugge M, de Boni M, Pennelli G, de Bona M, Giacomelli L, Fassan M, Basso D, Plebani M, Graham DY (2010) Gastritis OLGA-staging and gastric cancer risk: a twelve year clinicopathological follow-up study. Aliment Pharmacol Ther 31:1104-1111
97. el-Zimaity HM, Graham DY, al-Assi MT, Malaty H, Karttunen TJ, Graham DP, Huberman RM, Genta RM (1996) Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol 27:35-41 (Pubitemid 26015579)
98. Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, van Dekken H, Meijer J, van Grieken NC, Kuipers EJ (2010) The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 71:1150-1158
99. Guarner J, Herrera-Goepfert R, Mohar A, Sanchez L, Halperin D, Ley C, Parsonnet J (1999) Interobserver variability in application of the revised Sydney classification for gastritis. Hum Pathol 30:1431-1434 (Pubitemid 30032918)
100. Kuipers EJ (2003) In through the out door: serology for atrophic gastritis. Eur J Gastroenterol Hepatol 15:877-879 (Pubitemid 36904456)
101. Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M (2004) Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 11:141-147 (Pubitemid 39274096)
102. Graham DY, Nurgalieva ZZ, El-Zimaity HM, Opekun AR, Campos A, Guerrero L, Chavez A, Cardenas V (2006) Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol 4:306-314 (Pubitemid 43343886)
103. Haj-Sheykholeslami A, Rakhshani N, Amirzargar A, Rafiee R, Shahidi SM, Nikbin B, Khoshavi F, Massarrat S (2008) Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol 6:174-179 (Pubitemid 351172947)
104. Hartleb M, Wandzel P, Waluga M, Matyszczyk B, Boldys H, Romañczyk T (2004) Non-endoscopic diagnosis of multifocal atrophic gastritis; efficacy of serum gastrin-17, pepsinogens and Helicobacter pylori antibodies. Acta Gastroenterol Belg 67:320-326 (Pubitemid 40188052)
105. Iijima K, Abe Y, Kikuchi R, Koike T, Ohara S, Sipponen P, Shimosegawa T (2009) Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol 15:853-859
106. Inoue M, Kobayashi S, Matsuura A, Hamajima N, Tajima K, Tominaga S (1998) Agreement of endoscopic findings and serum pepsinogen levels as an indicator of atrophic gastritis. Cancer Epidemiol Biomarkers Prev 7:261-263 (Pubitemid 28353939)
107. Kim HY, Kim N, Kang JN, Park YS, Lee DH, Kim YR, Kim JS, Jung HC, Song IS (2009) Clinical meaning of pepsinogen test and Helicobacter pylori serology in the health check-up population in Korea. Eur J Gastroenterol Hepatol 21:606-612
108. Knight T, Wyatt J, Wilson A, Greaves S, Newell D, Hengels K, Corlett M,Webb P, Forman D, Elder J (1996) Helicobacter pylori gastritis and serum pepsinogen levels in a healthy population: development of a biomarker strategy for gastric atrophy in high risk groups. Br J Cancer 73:819-824 (Pubitemid 26105313)
109. Leja M, Kupcinkas L, Funka K, Sudraba A, Jonaitis L, Ivanauskas A, Janciauskas D, Kiudelis G, ChiuHM, Lin JT (2009) The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology. Dig Dis Sci 54:2377-2384
110. Ley C, Mohar A, Guarner J, Herrera-Goepfert R, Figueroa LS, Halperin D, Parsonnet J (2001) Screening markers for chronic atrophic gastritis in Chiapas, Mexico. Cancer Epidemiol Biomarkers Prev 10:107-112 (Pubitemid 32172428)
111. Nardone G, Rocco A, Staibano S, Mezza E, Autiero G, Compare D, De Rosa G, Budillon G (2005) Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Aliment Pharmacol Ther 22:1139-1146 (Pubitemid 41779522)
112. Pasechnikov VD, Chukov SZ, Kotelevets SM, Mostovov AN, Mernova VP, Polyakova MB (2005) Invasive and non-invasive diagnosis of Helicobacter pylori-associated atrophic gastritis: a comparative study. Scand J Gastroenterol 40:297-301 (Pubitemid 40476460)
113. Ricci C, Vakil N, Rugge M et al (2004) Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol 99:1910-1915 (Pubitemid 39421232)
114. Rollan A, Ferreccio C, Gederlini A, Serrano C, Torres J, Harris P (2006) Noninvasive diagnosis of gastric mucosal atrophy in an asymptomatic population with high prevalence of gastric cancer. World J Gastroenterol 12:7172-7178 (Pubitemid 44890649)
115. Sierra R, Une C, Ramírez V et al (2006) Association of serum pepsinogen with atrophic body gastritis in Costa Rica. Clin Exp Med 6:72-78
116. Sitas F, Smallwood R, Jewell D, Millard PR, NewellDG, Meuwissen SG, Moses S, Zwiers A, Forman D (1993) Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis. Cancer Epidemiol Biomarkers Prev 2:119-123
117. Storskrubb T, Aro P, Ronkainen J et al (2008) Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol 43:1448-1455
118. Sun LP, Gong YH, Wang L, Yuan Y (2007) Serum pepsinogen levels and their influencing factors: a population-based study in 6990 Chinese from North China. World J Gastroenterol 13:6562-6567
119. Wu KC, Li HT, Qiao TD et al (2004) Diagnosis of atrophic body gastritis in Chinese patients by measuring serum pepsinogen. Chin J Dig Dis 5:22-27 (Pubitemid 38401246)
120. Väänänen H, Vauhkonen M, Helske T et al (2003) Nonendoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 15:885-891 (Pubitemid 36904458)
121. Cao Q, Ran ZH, Xiao SD (2007) Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. J Dig Dis 8:15-22 (Pubitemid 46189205)
122. Chung HW, Kim JW, Lee JH, Song SY, Chung JB, Kwon OH, Lim JB (2009) Comparison of the validity of three biomarkers for gastric cancer screening: carcinoembryonic antigen, pepsinogens, and high sensitive C-reactive protein. J Clin Gastroenterol 43:19-26
123. Kiyohira K, Yoshihara M, Ito M, Haruma K, Tanaka S, Chayama K (2003) Serum pepsinogen concentration as a marker of Helicobacter pylori infection and the histologic grade of gastritis: evaluation of gastric mucosa by serum pepsinogen levels. J Gastroenterol 38:332-338 (Pubitemid 36626268)
124. Oksanen A, Sipponen P, Miettinen A, Sarna S, Rautelin H (2000) Evaluation of blood tests to predict normal gastric mucosa. Scand J Gastroenterol 35:791-795
125. Di Mario F, Cavallar LG, Moussa AM et al (2006) Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: relationship with inflammation, activity, and density of the bacterium. Dig Dis Sci 51:1791-1795 (Pubitemid 44546748)
126. Kreuning J, Lindeman J, Biemond I, Lamers CB (1995) Serological parameters in assessment of degree of gastritis in healthy volunteers. Dig Dis Sci 40:609-614
127. Con SA, Con-Wong R, Con-Chin GR et al (2007) Serum pepsinogen levels, Helicobacter pylori CagA status, and cytokine gene polymorphisms associated with gastric premalignant lesions in Costa Rica. Cancer Epidemiol Biomarkers Prev 16:2631-2636 (Pubitemid 351196318)
128. Dinis-RibeiroM, da Costa-Pereira A, Lopes C, Barbosa J, Guilherme M, Moreira-Dias L, Lomba-Viana H, Silva R, Abreu N, Lomba- Viana R (2004) Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia 6:449-456 (Pubitemid 39411081)
129. Urita Y, Hike K, Torii N, Kikuchi Y, Kanda E, Sasajima M, Miki K (2004) Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis. Dig Dis Sci 49:795-801 (Pubitemid 38870206)
130. de Vries AC, Haringsma J, de Vries RA, ter Borg F, Nagtzaam NM, Steyerberg EW, van Dekken H, Kuipers EJ (2009) The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice. Gastrointest Endosc 70:18-25
131. Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, Doi H, Yoshida H, Kawabe T, Omata M (2005) Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 54:764-768 (Pubitemid 40732089)
132. Yamaji Y, Watabe H, Yoshida H, Kawabe T, Wada R, Mitsushima T, Omata M (2009) High-risk population for gastric cancer development based on serum pepsinogen status and lifestyle factors. Helicobacter 14:81-86
133. Yanaoka K, Oka M, Mukoubayashi C et al (2008) Cancer highrisk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 17:838-845 (Pubitemid 351536414)
134. Yanaoka K, Oka M, Yoshimura N et al (2008) Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int J Cancer 123:917-926 (Pubitemid 352032422)
135. Ohata H, Kitauchi S, Yoshimura N et al (2004) Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 109:138-143 (Pubitemid 38160674)
136. Oishi Y, Kiyohara Y, Kubo M et al (2006) The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol 163:629-637
137. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Moreira-Dias L (2007) Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia. J Gastroenterol Hepatol 22:1594-1604 (Pubitemid 47383332)
138. Miki K, Fujishiro M, Kodashima S, Yahagi N (2009) Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc 21:78-81
139. Aromaa A, Kosunen TU, Knekt P, Maatela J, Teppo L, Heinonen OP, Härkönen M, Hakama MK (1996) Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer. Am J Epidemiol 144:142-149 (Pubitemid 26234992)
140. Fukuda H, Saito D, Hayashi S et al (1995) Helicobacter pylori infection, serum pepsinogen level and gastric cancer: a case- control study in Japan. Jpn J Cancer Res 86:64-71
141. Kikuchi S, Wada O, Miki K, Nakajima T, Nishi T, Kobayashi O, Inaba Y (1994) Serum pepsinogen as a new marker for gastric carcinoma among young adults. Research Group on Prevention of Gastric Carcinoma among Young Adults. Cancer 73:2695-2702 (Pubitemid 24166253)
142. Knekt P, Teppo L, Aromaa A, Rissanen H, Kosunen TU (2006) Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period. Int J Cancer 119:702-705 (Pubitemid 43955726)
143. Kodoi A, Yoshihara M, Sumii K, Haruma K, Kajiyama G (1995) Serum pepsinogen in screening for gastric cancer. J Gastroenterol 30:452-460
144. Kokkola A, Louhimo J, Puolakkainen P, Alfthan H, Haglund C, Rautelin H (2005) Helicobacter pylori infection and low serum pepsinogen I level as risk factors for gastric carcinoma. World J Gastroenterol 11:1032-1036 (Pubitemid 40347758)
145. Kwak MS, Kim N, Lee HS, Lee HE, Jung HC, Song IS (2010) Predictive power of serum pepsinogen tests for the development of gastric cancer in comparison to the histologic risk index. Dig Dis Sci 55:2275-2282
146. Miki K, Ichinose M, Kawamura N et al (1989) The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects. Jpn J Cancer Res 80:111-114 (Pubitemid 20027662)
147. Nomura AM, Stemmermann GN, Samloff IM (1980) Serum pepsinogen I as a predictor of stomach cancer. Ann Intern Med 93:537-540 (Pubitemid 10015174)
148. Parsonnet J, Samloff IM, Nelson LM, Orentreich N, Vogelman JH, Friedman GD (1993) Helicobacter pylori, pepsinogen, and risk for gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2:461-466
149. ParthasarathyG,MarojuNK,KateV,AnanthakrishnanN, Sridharmg (2007) Serum pepsinogen I and II levels in various gastric disorders with special reference to their use as a screening test for carcinoma stomach. Trop Gastroenterol 28:166-170
150. Ren JS, Kamangar F, Qiao YL, Taylor PR, Liang H, Dawsey SM, Liu B, Fan JH, Abnet CC (2009) Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. Gut 58:636-642
151. Sasazuki S, Inoue M, Iwasaki M, Otani T, Yamamoto S, Ikeda S, Hanaoka T, Tsugane S, Japan Public Health Center Study Group (2006) Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study. Cancer Epidemiol Biomarkers Prev 15:1341-1347 (Pubitemid 44125292)
152. Shiotani A, Iishi H, Uedo N, Kumamoto M, Nakae Y, Ishiguro S, Tatsuta M, Graham DY (2005) Histologic and serum risk markers for noncardia early gastric cancer. Int J Cancer 115:463-469 (Pubitemid 40663752)
153. So JB, Yeoh KG, Moochala S, Chachlani N, Ho J, Wong WK, Mack P, Goh PM (2002) Serum pepsinogen levels in gastric cancer patients and their relationship with Helicobacter pylori infection: a prospective study. Gastric Cancer 5:228-232 (Pubitemid 36605886)
154. Sugiu K, Kamada T, Ito M, Kaya S, Tanaka A, Kusunoki H, Hata J, Haruma K (2006) Anti-parietal cell antibody and serum pepsinogen assessment in screening for gastric carcinoma. Dig Liver Dis 38:303-307 (Pubitemid 44382356)
155. Yoshihara M, Hiyama T, Yoshida S, Ito M, Tanaka S, Watanabe Y, Haruma K (2007) Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case-control study. Scand J Gastroenterol 42:760-764 (Pubitemid 46763575)
156. Hattori Y, Tashiro H, Kawamoto T, Kodama Y (1995) Sensitivity and specificity of mass screening for gastric cancer using the measurement of serum pepsinogens. Jpn J Cancer Res 86:1210-1215
157. Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA (1999) Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 44:693-697 (Pubitemid 29195918)
158. Westerveld BD, Pals G, Lamers CB et al (1987) Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels. Cancer 59:952-958 (Pubitemid 17024651)
159. You WC, Blot WJ, Zhang L et al (1993) Serum pepsinogens in relation to precancerous gastric lesions in a population at high risk for gastric cancer. Cancer Epidemiol Biomarkers Prev 2:113-117
160. Yoshihara M, Sumii K, Haruma K, Kiyohira K, Hattori N, Kitadai Y, Komoto K, Tanaka S, Kajiyama G (1998) Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol 93:1090-1096 (Pubitemid 29080956)
161. Miki K, Ichinose M, Ishikawa KB et al (1993) Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res 84:1086-1090 (Pubitemid 23307845)
162. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y (2003) Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 98:735-739 (Pubitemid 36576295)
163. Pharoah PD, Guilford P, Caldas C, International Gastric Cancer Linkage Consortium (2001) Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121:1348-1353 (Pubitemid 33140452)
164. Fitzgerald RC, Hardwick R, Huntsman D et al (2010) Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 47:436-444
165. Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Järvinen HJ, Myrhøj T, Sunde L, Wijnen JT, Lynch HT (2008) The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 123:444-449 (Pubitemid 351842032)
166. Capelle LG, Van Grieken NC, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ, Vasen HF, Kuipers EJ (2010) Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 138:487-492
167. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M, Offerhaus JA (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119:1447-1453 (Pubitemid 32198669)
168. van Lier mg, Westerman AM, Wagner A, Looman CW, Wilson JH, de Rooij FW, Lemmens VE, Kuipers EJ, Mathus-Vliegen EM, van Leerdam ME (2011) High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut 60:141-147
169. Offerhaus GJ, Giardiello FM, Krush AJ, Booker SV, Tersmette AC, Kelley NC, Hamilton SR (1992) The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 102:1980-1982
170. Yaghoobi M, Bijarchi R, Narod SA (2009) Family history and the risk of gastric cancer. Br J Cancer 102:237-242
171. Bakir T, Can G, Erkul S, Siviloglu C (2000) Stomach cancer history in the siblings of patients with gastric carcinoma. Eur J Cancer Prev 9:401-408 (Pubitemid 32065953)
172. La Vecchia C, Negri E, Franceschi S, Gentile A (1992) Family history and the risk of stomach and colorectal cancer. Cancer 70:50-55
173. Palli D, Galli M, Caporaso NE, Cipriani F, Decarli A, Saieva C, Fraumeni JF Jr, Buiatti E (1994) Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev 3:15-18 (Pubitemid 24172516)
174. García-González MA, Lanas A, Quintero E et al (2007) Gastric cancer susceptibility is not linked to pro- and anti-inflammatory cytokine gene polymorphisms in whites: a nationwide multicenter study in Spain. Am J Gastroenterol 102:1878-1892 (Pubitemid 47301539)
175. Dhillon PK, Farrow DC, Vaughan TL et al (2001) Family history of cancer and risk of esophageal and gastric cancers in the United States. Int J Cancer 93:148-152 (Pubitemid 32544602)
176. Minami Y, Tateno H (2003) Associations between cigarette smoking and the risk of four leading cancers in Miyagi Prefecture, Japan: a multi-site case-control study. Cancer Sci 94:540-547 (Pubitemid 36849720)
177. Eto K, Ohyama S, Yamaguchi T,Wada T, Suzuki Y, Mitsumori N, Kashiwagi H, Anazawa S, Yanaga K, Urashima M (2006) Familial clustering in subgroups of gastric cancer stratified by histology, age group and location. Eur J Sur Oncol 32:743-748 (Pubitemid 44276008)
178. Hong SH, Kim JW, Kim HG, Park IK, Ryoo JW, Lee CH, Sohn YK, Lee JY (2006) Glutathione S-transferases (GSTM1, GSTT1 and GSTP1) and N-acetyltransferase 2 polymorphisms and the risk of gastric cancer. J Prev Med Public Health 39:135-140
179. Foschi R, Lucenteforte E, Bosetti C, Bertuccio P, Tavani A, La Vecchia C, Negri E (2008) Family history of cancer and stomach cancer risk. Int J Cancer 123:1429-1432
180. Bernini M, Barbi S, Roviello F, Scarpa A, Moore P, Pedrazzani C, Beghelli S, Marrelli D, de Manzoni G (2006) Family history of gastric cancer: a correlation between epidemiologic findings and clinical data. Gastric Cancer 9:9-13
181. Rokkas T, Sechopoulos P, Pistiolas D, Margantinis G, Koukoulis G (2010) Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol 22:1128-1133
182. IARCWorking Group on the Evaluation of Carcinogenic Risks to Humans (1994) Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 61:1-241
183. Figueiredo C, Machado JC, Pharoah P et al (2002) Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 94:1680-1687 (Pubitemid 35446836)
184. Amieva MR, El-Omar EM (2008) Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 134:306-323 (Pubitemid 350309334)
185. Machado JC, Figueiredo C, Canedo P et al (2003) A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 125:364-371 (Pubitemid 36929416)
186. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH (2003) Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 125:1636-1644 (Pubitemid 37500427)
187. Basso D, Zambon CF, Letley DP et al (2008) Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology 135:91-99 (Pubitemid 351899019)
188. El-Omar EM, Carrington M, Chow WH (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398-402 (Pubitemid 30164342)
189. Yin M, Hu Z, Tan D, Ajani JA, Wei Q (2009) Molecular epidemiology of genetic susceptibility to gastric cancer: focus on single nucleotide polymorphisms in gastric carcinogenesis. Am J Transl Res 1:44-54
190. Persson C, Canedo P, Machado JC, El-Omar EM, Forman D (2011) Polymorphisms in inflammatory response genes and their association with gastric cancer: a HuGE systematic review and meta-analyses. Am J Epidemiol 173:259-270
191. Wang P, Xia HH, Zhang JY, Dai LP, Xu XQ, Wang KJ (2007) Association of interleukin-1 gene polymorphisms with gastric cancer: a meta-analysis. Int J Cancer 120:552-562 (Pubitemid 44969026)
192. Camargo MC, Mera R, Correa P, Peek RM Jr, Fontham ET, Goodman KJ, Piazuelo MB, Sicinschi L, Zabaleta J, Schneider BG (2006) Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:1674-1687 (Pubitemid 44497104)
193. Xue H, Lin B, Ni P, Xu H, Huang G (2010) Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol 25:1604-1617
194. Kamangar F, Cheng C, Abnet CC, Rabkin CS (2006) Interleukin- 1B polymorphisms and gastric cancer risk-a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:1920-1928 (Pubitemid 44664269)
195. Loh M, Koh KX, Yeo BH, Song CM, Chia KS, Zhu F, Yeoh KG, Hill J, Iacopetta B, Soong R (2009) Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer 45:2562-2568
196. Schlemper RJ, Riddell RH, Kato Yet al (2000) The Vienna classification of gastrointestinal epithelial neoplasia. Gut 47:251-255 (Pubitemid 30489769)
197. Rugge M, Leandro G, Farinati F, Di Mario F, Sonego F, Cassaro M, Guido M, Ninfo V (1995) Gastric epithelial dysplasia. How clinicopathologic background relates to management. Cancer 76:376-382
198. Rugge M, Cassaro M, Di Mario F, Leo G, Leandro G, Russo VM, Pennelli G, Farinati F, Interdisciplinary Group on Gastric Epithelial Dysplasia (IGGED) (2003) The long term outcome of gastric non-invasive neoplasia. Gut 52:1111-1116 (Pubitemid 36877421)
199. de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ (2010) Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 59:1030-1036
200. Stryker SJ,Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL (1987) Natural history of untreated colonic polyps. Gastroenterology 93:1009-1013 (Pubitemid 18000643)
201. Munkholm P (2003) Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18(Suppl 2):1-5 (Pubitemid 37174709)
202. Weinstein WM, Goldstein N (1994) Gastric dysplasia and its management. Gastroenterology 107:1543-1559
203. Ching CK (1995) Can we justify resecting all gastric epithelial dysplastic lesions? Gastroenterology 108:1955-1956
204. Abraham SC, Montgomery EA, Singh VK, Yardley JH, Wu TT (2000) Gastric adenomas: intestinal type and gastric type adenomas differ in the risk of adenocarcinoma and presence of background mucosal pathology. Am J Surg Pathol 26:1276-1285
205. Hosokawa O, Watanabe K, Hatorri M, Douden K, Hayashi H, Kaizaki Y (2001) Detection of gastric cancer by repeat endoscopy within a short time after negative examination. Endoscopy 33:301-305 (Pubitemid 32586418)
206. de Dombal FT, Price AB, Thompson H, Williams GT, Morgan AG, Softley A, Clamp SE, Unwin BJ (1990) The British Society of Gastroenterology early gastric cancer/dysplasia survey: an interim report. Gut 31:115-120 (Pubitemid 20037992)
207. Sipponen P, Kekki M, Siurali M (1983) Atrophic chronic gastritis and intestinal metaplasia in gastric cancer: comparison with a representative population sample. Cancer 52:1062-1068 (Pubitemid 13050773)
208. Hull MJ, Mino-Kenudson M, Nishioka NS et al (2006) Endoscopic mucosal resection: an improved diagnostic procedure for early gastroesophageal epithelial neoplasms. Am J Surg Pathol 30:114-118 (Pubitemid 43740217)
209. Kim YJ, Park JC, Kim JH, Shin SK, Lee SK, Lee YC, Chung JB (2010) Histologic diagnosis based on forceps biopsy is not adequate for determining endoscopic treatment of gastric adenomatous lesions. Endoscopy 42:620-626
210. Kim ES, Jeon SW, Park SY et al (2009) Where has the tumor gone? The characteristics of cases of negative pathologic diagnosis after endoscopic mucosal resection. Endoscopy 41:739-745
211. Cassaro M, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM (2000) Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 95:1431-1438 (Pubitemid 30396299)
212. Morson BC (1955) Carcinoma arising from areas of intestinal metaplasia in the gastric mucosa. Br J Cancer 9:377-385
213. Vannella L, Lahner E, Osborn J, Bordi C, Miglione M, Delle Fave G, Annibale B (2010) Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther 31:1042-1050
214. Lahner E, Bordi C, Cattaruzza MS, Iannoni C, Milione M, Delle Fave G, Annibale B (2005) Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther 22:471-481 (Pubitemid 41248115)
215. Van Zanten SJ, Dixon MF, Lee A (1999) The gastric transitional zones: neglected links between gastroduodenal pathology and helicobacter ecology. Gastroenterology 116:1217-1229 (Pubitemid 29203032)
216. Kimura A, Takemoto T (1969) An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1:87-97
217. Rokkas T, Filipe MI, Sladen GE (1991) Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 32:1110-1113
218. Tosi P, Filipe MI, Luzi P, Miracco C, Santopietro R, Lio R, Sforza V, Barbini P (1993) Gastric intestinal metaplasia type III cases are classified as low-grade dysplasia on the basis of morphometry. J Pathol 169:73-78 (Pubitemid 23034426)
219. Ramesar KC, Sanders DS, Hopwood D (1987) Limited value of type III intestinal metaplasia in predicting risk of gastric carcinoma. J Clin Pathol 40:1287-1290 (Pubitemid 18015256)
220. Conchillo JM, Houben G, de Bruïne A, Stockbrügger R (2001) Is type III intestinal metaplasia an obligatory precancerous lesion in intestinal-type gastric carcinoma? Eur J Cancer Prev 10:307-312 (Pubitemid 32735346)
221. Nozaki K, Shimizu N, Ikehara Y, Inoue M, Tsukamoto T, Inada K, Tanaka H, Kumagai T, Kaminishi M, Tatematsu M (2003) Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci 94:235-239 (Pubitemid 36575888)
222. Shimizu N, Ikehara Y, Inada K et al (2000) Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res 60:1512-1514 (Pubitemid 30183416)
223. Maruta F, Sugiyama A, Ishizone S, Miyagawa S, Ota H, Katsuyama T (2005) Eradication of Helicobacter pylori decreases mucosal alterations linked to gastric carcinogenesis in Mongolian gerbils. J Gastroenterol 40:104-105 (Pubitemid 40796340)
224. Pimanov SI, Makarenko EV, Voropaeva AV, Matveenko ME, Voropaev EV (2008) Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer. J Gastroenterol Hepatol 23:1666-1671
225. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G (2007) The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 12(Suppl 2):32-38 (Pubitemid 350076224)
226. de Vries AC, Kuipers EJ (2007) Review article: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 26(Suppl 2):25-35 (Pubitemid 350233320)
227. Wang J, Xu L, Shi R, Huang X, Li SW, Huang Z, Zhang G (2011) Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 83:253-260
228. Annibale B, Aprile MR, D'ambra G, Caruana P, Bordi C, Delle Fave G (2000) Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECLcell hyperplasia. Aliment Pharmacol Ther 14:625-634 (Pubitemid 30240756)
229. Satoh K, Kimura K, Takimoto T, Kihira K (1998) A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of Helicobacter pylori. Helicobacter 3:236-240 (Pubitemid 128656775)
230. Correa P, Fontham ET, Bravo JC et al (2000) Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 92:1881-1888 (Pubitemid 32036918)
231. Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, Correa P (2005) Long term follow up of patients treated for Helicobacter pylori infection. Gut 54:1536-1540 (Pubitemid 41531767)
232. Wong BC, Lam SK, Wong WM (2004) Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291:187-194 (Pubitemid 38082812)
233. Fuccio L, Zagari RM, Minardi ME, Bazzoli F (2007) Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 25:133-141 (Pubitemid 46046370)
234. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F (2009) Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 151:121-128
235. Kim N, Park RY, Cho SI, Lim SH, Lee KH, Lee W, Kang HM, Lee HS, Jung HC, Song IS (2008) Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. J Clin Gastroenterol 42:448-454 (Pubitemid 351572254)
236. Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, Lau JY, Sung JJ (2004) Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 53:1244-1249 (Pubitemid 39120105)
237. You WC, Brown LM, Zhang L et al (2006) Randomized doubleblind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 98:974-983 (Pubitemid 44288162)
238. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H, Shiratori Y (2005) The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 100:1037-1042 (Pubitemid 40769039)
239. Take S, Mizuno M, Ishiki K, Yoshida T, Ohara N, Yokota K, Oguma K, Okada H, Yamamoto K (2011) The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol 46:318-324
240. Fukase K, Kato M, Kikuchi S et al (2008) Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an openlabel, randomised controlled trial. Lancet 372:392-397
241. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajiyama G (1997) Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 6:639-642 (Pubitemid 27342688)
242. Toyokawa T, Suwaki K, Miyake Y, Nakatsu M, Ando M (2010) Eradication of Helicobacter pylori infection improved gastric mucosal atrophy and prevented progression of intestinal metaplasia, especially in the elderly population: a long-term prospective cohort study. J Gastroenterol Hepatol 25:544-547
243. Yang HB, Sheu BS, Wang ST, Cheng HC, Chang WL, Chen WY (2009) H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using longterm esomeprazole. Am J Gastroenterol 104:1642-1649
244. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56:772-781 (Pubitemid 46854190)
245. Lam SK, Talley NJ (1998) Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 13:1-12 (Pubitemid 28137751)
246. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G, European Helicobacter Pylori Study Group (EHPSG) (2002) Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16:167-180 (Pubitemid 34146357)
247. Fock KM, Katelaris P, Sugano K (2009) Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 24:1587-1600
248. Shin DW, Yun YH, Choi IJ, Koh E, Park SM (2009) Cost- effectiveness of eradication of Helicobacter pylori in gastric cancer survivors after endoscopic resection of early gastric cancer. Helicobacter 14:536-544
249. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC (2003) Nonsteroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 95:1784-1791 (Pubitemid 38008901)
250. Tian W, Zhao Y, Liu S, Li X (2010) Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev 19:288-298
251. Leung WK, Ng EK, Chan FK, Chan WY, Chan KF, Auyeung AC, Lam CC, Lau JY, Sung JJ (2006) Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clin Cancer Res 12:4766-4772 (Pubitemid 44297831)
252. Zhang LJ, Wang SY, Huo XH et al (2009) Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions. World J Gastroenterol 15:2731-2738
253. Hung KH, Yang HB, Cheng HC,Wu JJ, Sheu BS (2010) Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication. J Gastroenterol Hepatol 25:48-53
254. Yanaoka K, Oka M, Yoshimura N et al (2010) Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Int J Cancer 126:1467-1473
255. Yang HB, Cheng HC, Sheu BS, Hung KH, Liou MF, Wu JJ (2007) Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. Aliment Pharmacol Ther 25:455-461
256. Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT (2010) Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pyloriinfected patients. J Clin Oncol 28:2952-2957
257. Plummer M, Vivas J, Lopez G et al (2007) Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population. J Natl Cancer Inst 99:137-146
258. Mason J, Axon AT, Forman D et al (2002) The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther 16:559-568 (Pubitemid 34214537)
259. Parsonnet J, Harris RA, Hack HM, Owens DK (1996) Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 348:150-154 (Pubitemid 26238097)
260. Davies R, Crabbe D, Roderick P, Goddard JR, Raftery J, Patel P (2002) A simulation to evaluate screening for Helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers. Health Care Manag Sci 5:249-258 (Pubitemid 41450970)
261. Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Bhandari P, Patel P (2003) The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. Health Technol Assess 7:1-86
262. Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Patel P, Bhandari P (2003) Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen 10:148-156 (Pubitemid 38296852)
263. Leivo T, Salomaa A, Kosunen TU, Tuominen R, Färkkilä M, Linna M, Sintonen H (2004) Cost-benefit analysis of Helicobacter pylori screening. Health Policy 70:85-96 (Pubitemid 39092961)
264. Dan YY, So JB, Yeoh KG (2006) Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol 4:709-716 (Pubitemid 43825816)
265. Yeh JM, Kuntz KM, Ezzati M, Goldie SJ (2009) Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer 124:157-166
266. Lee YC, Lin JT, Wu HM, Liu TY, Yen MF, Chiu HM, Wang HP, Wu MS, Hsiu-Hsi Chen T (2007) Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev 16:875-885
267. Lee HY, Park EC, Jun JK, Choi KS, Hahm MI (2010) Comparing upper gastrointestinal X-ray and endoscopy for gastric cancer diagnosis in Korea. World J Gastroenterol 16:245-250
268. Xie F, Luo N, Blackhouse G, Goeree R, Lee HP (2008) Cost- effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese. Int J Technol Assess Health Care 24:87-95 (Pubitemid 351158547)
269. Xie F, Luo N, Lee HP (2008) Cost effectiveness analysis of population-based serology screening and 13C-urea breath test for Helicobacter pylori to prevent gastric cancer: a Markov model. World J Gastroenterol 14:3021-3027
270. Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM (1999) Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 159:142-148 (Pubitemid 29055101)
271. Yeh JM, Hur C, Kuntz KM, Ezzati M, Goldie SJ (2010) Cost- effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer 116:2941-2953
272. Hassan C, Zullo A, Di Giulio E, Annibale B, Lahner E, De Francesco V, Ierardi E (2010) Cost-effectiveness of endoscopic surveillance for gastric intestinal metaplasia. Helicobacter 15:221-226